Merck Beats Estimates on Diabetes Drug Sales

Net income was $1.51 billion, or 49 cents a share, compared with a loss of $531 million, or 17 cents, a year earlier when Merck took a $1.7 billion charge to write down the value of an experimental blood thinner, the Whitehouse Station, New Jersey- based company said today in a statement. Earnings excluding one- time items of 97 cents a share beat by 2 cents the average of 18 analyst estimates compiled by Bloomberg.

Merck forecast full-year earnings excluding one-time items of $3.75 to $3.85 a share, in range of analyst estimates of $3.84. The company is trimming jobs to reduce costs as it prepares for generic competition to the asthma medication Singulair, coming in August. Merck introduced a hepatitis C drug last year and is working on another.

“In terms of top line, it is a modest growth,” said Aparna Krishnan, an analyst at IHS Global Insight in London, in a phone interview. “They face lots of pressure in 2012. It is going to be very challenging.”

Revenue rose 1.7 percent to $12.3 billion, less than the analyst estimates of $12.5 billion.

Sales of Januvia for diabetes jumped 42 percent to $960 million, while revenue of the company’s human papillomavirus vaccine Gardasil increased 24 percent to $274 million.

Vytorin Decline

Those gains were countered by a 16 percent decline in sales for the cholesterol drug Vytorin and a 28 percent drop for the arthritis drug Remicade. In July, Merck transferred exclusive Remicade marketing rights in South and Central America, the Middle East, Canada, Africa, and Asia Pacific to Johnson & Johnson.

“It was a decent fourth-quarter overall,” said Timothy Anderson, an analyst at Sanford C. Bernstein analyst in New York, in a note to clients today.

Merck fell less than 1 percent to $38.42 at 9:38 a.m. in New York trading.

Merck said that it expected 2012 sales to be “at or near” 2011 levels on a constant currency basis. Assuming current exchange rates, sales would decline 2 percent to 3 percent from 2011, the company said. Analysts had expected 2012 sales of $47.6 billion. The company said that research and development spending would be little changed in 2012.

In July, Merck said it would eliminate another 12,000 to 13,000 jobs by 2015, expanding a restructuring program that cut 11,500 positions in 2010.




Leave a Reply

Reset password

Enter your email address and we will send you a link to change your password.

Get started with your account

to save your favourite homes and more

Sign up with email

Get started with your account

to save your favourite homes and more

By clicking the «SIGN UP» button you agree to the Terms of Use and Privacy Policy
Powered by Estatik
error: Content is protected !!